Equities research analysts expect that Ionis Pharmaceuticals Inc (NASDAQ:IONS) will announce ($0.30) earnings per share for the current quarter, Zacks Investment Research reports. Five analysts have made estimates for Ionis Pharmaceuticals’ earnings. The highest EPS estimate is ($0.07) and the lowest is ($0.53). Ionis Pharmaceuticals posted earnings of ($0.03) per share during the same quarter last year, which indicates a negative year over year growth rate of 900%. The business is expected to report its next quarterly earnings results on Tuesday, November 5th.

According to Zacks, analysts expect that Ionis Pharmaceuticals will report full year earnings of ($0.22) per share for the current financial year, with EPS estimates ranging from ($0.97) to $0.24. For the next year, analysts anticipate that the firm will post earnings of $0.51 per share, with EPS estimates ranging from ($1.51) to $4.50. Zacks’ earnings per share averages are a mean average based on a survey of analysts that follow Ionis Pharmaceuticals.

Ionis Pharmaceuticals (NASDAQ:IONS) last posted its earnings results on Wednesday, August 7th. The company reported ($0.01) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.27) by $0.26. Ionis Pharmaceuticals had a net margin of 49.90% and a return on equity of 38.70%. The firm had revenue of $164.00 million for the quarter, compared to the consensus estimate of $145.31 million. During the same period in the previous year, the firm posted ($0.29) EPS. The business’s quarterly revenue was up 39.0% on a year-over-year basis.

A number of research firms have recently weighed in on IONS. Piper Jaffray Companies set a $75.00 target price on shares of Ionis Pharmaceuticals and gave the stock a “hold” rating in a report on Friday, May 24th. Zacks Investment Research downgraded shares of Ionis Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday, July 31st. BMO Capital Markets reduced their target price on shares of Ionis Pharmaceuticals from $96.00 to $95.00 and set an “outperform” rating on the stock in a report on Wednesday, July 24th. Evercore ISI set a $76.00 target price on shares of Ionis Pharmaceuticals and gave the stock a “hold” rating in a report on Wednesday, August 7th. Finally, TheStreet downgraded shares of Ionis Pharmaceuticals from a “b-” rating to a “c” rating in a report on Thursday, August 8th. Nine equities research analysts have rated the stock with a hold rating and one has assigned a buy rating to the stock. The company has a consensus rating of “Hold” and a consensus target price of $67.78.

In related news, Director Spencer R. Berthelsen sold 15,000 shares of Ionis Pharmaceuticals stock in a transaction dated Monday, June 24th. The shares were sold at an average price of $63.67, for a total transaction of $955,050.00. Following the completion of the transaction, the director now directly owns 99,404 shares of the company’s stock, valued at approximately $6,329,052.68. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Stanley T. Crooke sold 10,000 shares of Ionis Pharmaceuticals stock in a transaction dated Thursday, July 18th. The stock was sold at an average price of $70.25, for a total transaction of $702,500.00. Following the transaction, the chief executive officer now directly owns 79,634 shares of the company’s stock, valued at $5,594,288.50. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 40,210 shares of company stock valued at $2,650,844. 2.40% of the stock is owned by corporate insiders.

Several hedge funds have recently added to or reduced their stakes in the stock. Ladenburg Thalmann Financial Services Inc. boosted its stake in shares of Ionis Pharmaceuticals by 1.0% during the 2nd quarter. Ladenburg Thalmann Financial Services Inc. now owns 16,084 shares of the company’s stock worth $1,040,000 after purchasing an additional 154 shares during the period. Northwestern Mutual Wealth Management Co. boosted its stake in shares of Ionis Pharmaceuticals by 12.1% during the 1st quarter. Northwestern Mutual Wealth Management Co. now owns 1,485 shares of the company’s stock worth $121,000 after purchasing an additional 160 shares during the period. Carroll Financial Associates Inc. boosted its stake in shares of Ionis Pharmaceuticals by 27.4% during the 1st quarter. Carroll Financial Associates Inc. now owns 762 shares of the company’s stock worth $61,000 after purchasing an additional 164 shares during the period. Comerica Bank boosted its stake in shares of Ionis Pharmaceuticals by 1.1% during the 2nd quarter. Comerica Bank now owns 15,590 shares of the company’s stock worth $1,051,000 after purchasing an additional 170 shares during the period. Finally, Coastal Investment Advisors Inc. boosted its stake in shares of Ionis Pharmaceuticals by 1.7% during the 2nd quarter. Coastal Investment Advisors Inc. now owns 10,023 shares of the company’s stock worth $640,000 after purchasing an additional 172 shares during the period. 82.65% of the stock is owned by hedge funds and other institutional investors.

Shares of Ionis Pharmaceuticals stock traded up $1.60 during trading hours on Friday, reaching $69.08. The company’s stock had a trading volume of 603,500 shares, compared to its average volume of 1,244,549. The firm has a 50 day moving average price of $65.93 and a 200-day moving average price of $68.72. Ionis Pharmaceuticals has a one year low of $43.27 and a one year high of $86.58. The company has a debt-to-equity ratio of 0.45, a current ratio of 10.01 and a quick ratio of 9.36. The stock has a market cap of $9.40 billion, a P/E ratio of 23.34 and a beta of 2.07.

Ionis Pharmaceuticals Company Profile

Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; and TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.

Featured Article: What is the Rule of 72?

Get a free copy of the Zacks research report on Ionis Pharmaceuticals (IONS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Ionis Pharmaceuticals (NASDAQ:IONS)

Receive News & Ratings for Ionis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.